Claret says it latest fund will have larger focus on European life sciences

European growth debt fund Claret Capital Partners raises €575M, with a third earmarked for biotech, medtech and diagnostics deals. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo…

Anna Brown · 2026-09-07

European firm Claret Capital Partners has raised €575 million in its latest round, dubbed Fund IV, and a sizable portion will be lent out to local biotech companies and manufacturers. Roughly one third of the ...

Source: Endpoints News